US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Following the departure of Christophe Bourdon in December, US drugmaker Alexion Pharmaceuticals has named his replacement in the role of senior vice president and head of Europe/Middle East/Africa/Canada (EMEAC). 30 January 2018
A long-standing leader in health technology assessment (HTA) in the UK and internationally has taken a step across the divide to become a leading lobbyist for pharma. 25 January 2018
Belgian biotech firm Ablynx today announced the appointment of Robert Friesen as chief scientific officer (CSO), effective March 1, 2018. 24 January 2018
Merck & Co UK unit MSD has today announced the appointment of Dr Fiona Marshall to lead its new discovery research facility in London, focused on early bioscience discovery and entrepreneurial innovation. 22 January 2018
Japanese GPCR medicines specialist Sosei Group today announced that Dr Fiona Marshall has resigned from her position as executive vice president and chief scientific officer of Sosei to assume a senior role outside the company. 19 January 2018
Jordan-headquartered Hikma Pharmaceuticals today announced that Surendera Tyagi will join the company as group chief scientific officer and global head of R&D. 15 January 2018
Novartis today revealed that Elizabeth (Liz) Barrett, currently global president oncology at Pfizer, will join the company as chief executive of Novartis Oncology and a member of the executive committee of Novartis, effective February 1, 2018 11 January 2018
French drugmaker Ipsen today announced the promotion of Dr Aidan Murphy as executive vice president, technical operations, effective January 1, 2018. 10 January 2018
Dr Peter Fellner, who has served as chairman of Belgian biotech firm Ablynx since 2013, has decided to resign from the board with immediate effect. 9 January 2018
US biotech Neurocrine Biosciences has named an experienced Eli Lilly executive its new chief medical officer after Christopher O'Brien announced that he would be retiring. 8 January 2018
Ophthalmic drug specialist Aerie Pharmaceuticals has appointed Julia Williams as director of medical affairs, initially focused on the launch of Rhopressa (netarsudil ophthalmic solution) 0.02%. 3 January 2018
US biotech firm Array BioPharma has launched a new subsidiary to develop drugs using its ARRY-797 drug program, according to a filing with the US Securities and Exchange Commission (SEC). 30 December 2017
Robert Stewart is to leave his role as chief operating officer of Ireland-incorporated drugmaker Allergan to take the top job at Amneal Pharmaceuticals. 18 December 2017
In a candid admission, privately-owned German pharma major Boehringer Ingelheim has said that conflicting views over strategy are behind the departure of one of its most senior executives. 18 December 2017
In today’s world, cheap insults from people in high places – whether justified and evidence-backed or not – can do harm to the reputation and market value of pharma firms that can be difficult to repair. 15 December 2017
Clinical-stage US biotech Provectus Biopharmaceuticals has reached a settlement with the US Securities and Exchange Commission (SEC) in connection with investigations relating to two former executives and the company. 13 December 2017